Abstract
The facultative intracellular pathogen and zoonotic agent Brucella sp. possesses two carbonic anhydrases (CAs, EC 4.2.1.1), termed bsCA I and bsCA II (in Brucella suis), belonging to the β-class of these metalloproteins. These zinc enzymes, present in many other pathogenic bacteria, have been considered recently as potential antibacterial targets. The catalytic activity of bsCA II is higher than that of bsCA I (for the conversion of CO2 to bicarbonate). Both enzymes were inhibited by the well-studied inhibitor acetazolamide, a sulfonamide drug. A library of 41 sulfonamides and one sulfamate, among which were 13 clinically tested drugs, was used for inhibition studies with bsCA I and II. These compounds were generally much more potent inhibitors of bsCA I (KIs of 17-75 nM) than of bsCA II (KIs of 84-923nM). However, certain glycosidic sulfonamide derivatives exhibited the same strong inhibitory activity on both bsCA I and bsCA II (KIs of 8.9-20 nM). Furthermore, at least one of these glycosylsulfonamides showed a significant inhibition of B. suis growth after 8-11 days of culture in minimal medium. In conclusion, as β-CAs of Brucella are susceptible to inhibition by a wide range of aromatic and heteroaromatic sulfonamides, they may represent novel targets for the development of clinically useful antibacterial agents.
Keywords: β-carbonic anhydrase, Brucella suis, inhibition, brucellosis, sulfonamide, zoonotic agent, carbonic anhydrases, metalloproteins, acetazolamide, sulfonamide drug, glycosidic sulfonamide, glycosylsulfonamides, cocco-bacilli, dendritic cells, Helicobacter pylori, Mycobacterium tuberculosis, bsCA I, sulfamate, methazolamide, ethoxzolamide, dichorophenamide, dorzolamide, brinzolamide, benzolamide, topiramate, zonisamide, sulpiride, indisulam, celecoxib, valdecoxib, glycosylsulfonamide
Current Pharmaceutical Design
Title: Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents
Volume: 16 Issue: 29
Author(s): Jean-Yves Winum, Stephan Kohler and Claudiu T. Supuran
Affiliation:
Keywords: β-carbonic anhydrase, Brucella suis, inhibition, brucellosis, sulfonamide, zoonotic agent, carbonic anhydrases, metalloproteins, acetazolamide, sulfonamide drug, glycosidic sulfonamide, glycosylsulfonamides, cocco-bacilli, dendritic cells, Helicobacter pylori, Mycobacterium tuberculosis, bsCA I, sulfamate, methazolamide, ethoxzolamide, dichorophenamide, dorzolamide, brinzolamide, benzolamide, topiramate, zonisamide, sulpiride, indisulam, celecoxib, valdecoxib, glycosylsulfonamide
Abstract: The facultative intracellular pathogen and zoonotic agent Brucella sp. possesses two carbonic anhydrases (CAs, EC 4.2.1.1), termed bsCA I and bsCA II (in Brucella suis), belonging to the β-class of these metalloproteins. These zinc enzymes, present in many other pathogenic bacteria, have been considered recently as potential antibacterial targets. The catalytic activity of bsCA II is higher than that of bsCA I (for the conversion of CO2 to bicarbonate). Both enzymes were inhibited by the well-studied inhibitor acetazolamide, a sulfonamide drug. A library of 41 sulfonamides and one sulfamate, among which were 13 clinically tested drugs, was used for inhibition studies with bsCA I and II. These compounds were generally much more potent inhibitors of bsCA I (KIs of 17-75 nM) than of bsCA II (KIs of 84-923nM). However, certain glycosidic sulfonamide derivatives exhibited the same strong inhibitory activity on both bsCA I and bsCA II (KIs of 8.9-20 nM). Furthermore, at least one of these glycosylsulfonamides showed a significant inhibition of B. suis growth after 8-11 days of culture in minimal medium. In conclusion, as β-CAs of Brucella are susceptible to inhibition by a wide range of aromatic and heteroaromatic sulfonamides, they may represent novel targets for the development of clinically useful antibacterial agents.
Export Options
About this article
Cite this article as:
Winum Jean-Yves, Kohler Stephan and T. Supuran Claudiu, Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents, Current Pharmaceutical Design 2010; 16 (29) . https://dx.doi.org/10.2174/138161210793429850
DOI https://dx.doi.org/10.2174/138161210793429850 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Evolution and Analysis of Heterogeneity in the Clinical Expression of Aortic Diseases Similar to Marfan’s Syndrome: Challenge and Art in Clinical Diagnosis
Current Rheumatology Reviews Anionic Antimicrobial Peptides from Eukaryotic Organisms and their Mechanisms of Action
Current Chemical Biology Ethanol and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review
Current Respiratory Medicine Reviews Structure and Function of the Type III Secretion System of Pseudomonas aeruginosa
Current Protein & Peptide Science Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews Candida parapsilosis Secreted Lipase as an Important Virulence Factor
Current Protein & Peptide Science MRSA Infections: From Classical Treatment to Suicide Drugs
Current Medicinal Chemistry FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Unique Applications of Novel Antifungal Drug Combinations
Anti-Infective Agents in Medicinal Chemistry Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Prevalence and Resistance Profiles of Vancomycin-resistant Enterococcal Isolates in Iran; An Eight-month Report from Nine Major Cities
Infectious Disorders - Drug Targets Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine Development
Current Pharmaceutical Design Prevention of Microbial Communities: Novel Approaches Based Natural Products
Current Pharmaceutical Biotechnology Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)
Current Pharmaceutical Design Disseminated TB in an Immunocompetent Patient: A Case Report
Infectious Disorders - Drug Targets The Role of the Coagulase-negative Staphylococci (CoNS) in Infective Endocarditis; A Narrative Review from 2000 to 2020
Current Pharmaceutical Biotechnology